Is this you? Create Your Porfile
Avatar

Nicholas Charles Ray

AstraZeneca

Network

Latest external collaboration on country level. Dive into details by clicking on the dots.

Explore More

Hotspot

Dive into the research topics where Nicholas Charles Ray is active.

Explore More

Publication

Featured researches published by Nicholas Charles Ray.

Archive | 2007

Nitrogen containing heterocyclic compounds useful as m3-receptor modulators

Richard James Bull; Den Heuvel Marco Van; Antonio Mete; Alan John Nadin; Nicholas Charles Ray

Archive | 2008

Heterocyclic Derivatives as M3 Muscarinic Receptors

Barbara Giuseppina Avitabile; Harry Finch; Jamie Knight; Alan John Nadin; Nicholas Charles Ray

Archive | 2009

PHARMACEUTICAL PRODUCT COMPRISING A MUSCARINIC RECEPTOR ANTAGONIST AND A Beta2-ADRENOCEPTOR AGONIST

Barbara Guiseppina Avitabile; Alan John Nadin; Nicholas Charles Ray

Archive | 2009

Pharmaceutical product comprising a muscarinic receptor antagonist and a second active ingredient

Barbara Guiseppina Avitabile; Alan John Nadin; Nicholas Charles Ray

Archive | 2012

TETRAHYDROPYRROLOPYRIMIDINEDIONES AND THEIR USE IN THERAPY

Nicholas Charles Ray; Harry Finch; Christine Edwards; Elizabeth O'connor

Archive | 2009

Azonia bicycloalkanes as m3 muscarinic acetylcholin receptor antagonists

Richard James Bull; Alan John Nadin; Nicholas Charles Ray; Phillip Smith

Archive | 2008

Heterocyclic compounds used in the treatment of diseases where enhanced m3 receptor activation is implicated

Alan John Nadin; Susan Elizabeth Osbourn; Patrizia Tisselli; Nicholas Charles Ray

Archive | 2010

Cyclic amine derivatives having beta2 adrenergic receptor agonist and muscarinic receptor antagonist activity

David Donald; Andrew Stephen Robert Jennings; Nicholas Charles Ray; Fabien Roussel; Jonathan Mark Sutton; Patrizia Tisselli; Michelle Wilson

Archive | 2009

2- (9h-xanthen-9-yl) -oxazol derivatives as m3 muscarinic receptor antagonists for the treatment of asthma and chronic obstructive lung disease

Richard James Bull; Nicholas Charles Ray

Archive | 2017

inibição de enzimas

Carmelida Capaldi; Jonathan Mark Sutton; Nicholas Charles Ray; Robert Heald

Explore More

Collaboration

Dive into the Nicholas Charles Ray's collaboration.

Top Co-Authors
Avatar

Alan John Nadin

AstraZeneca

View shared research outputs
Top Co-Authors
Avatar

Jonathan Mark Sutton

Chiesi Farmaceutici S.p.A.

View shared research outputs
Top Co-Authors
Avatar

Barbara Guiseppina Avitabile

AstraZeneca

View shared research outputs
Top Co-Authors
Avatar

Richard James Bull

AstraZeneca

View shared research outputs
Top Co-Authors
Avatar

David Donald

Loughborough University

View shared research outputs
Top Co-Authors
Avatar

Harry Finch

University of Hertfordshire

View shared research outputs
Top Co-Authors
Avatar

Fabien Roussel

Janssen Pharmaceutica

View shared research outputs
Top Co-Authors
Avatar

Patrizia Tisselli

Janssen Pharmaceutica

View shared research outputs
Top Co-Authors
Avatar

Carmelida Capaldi

University of Bari

View shared research outputs
Top Co-Authors
Avatar

Robert Heald

University of Arizona

View shared research outputs
Explore More
Researchain Logo
Decentralizing Knowledge